Search the GHTC website

Global health R&D delivers for Indiana

US government investment in global health R&D has delivered

$192.9 million
to Indiana research institutions
2,400+ new jobs
for Indiana
Indiana's top USG-funded global health R&D institutions

Indiana's top USG-funded global health R&D institutions

Indiana University-Purdue University Indianapolis
$58.2 million
University of Notre Dame
$54.1 million
Purdue University
$33.9 million
$28.5 million
Indiana University Bloomington
$11.7 million
Regenstrief Institute
$4.7 million
Butler University
$378 thousand
Aarden Pharmaceuticals Inc.*
$313 thousand
Kovina Therapeutics Inc.
$299 thousand
Earlham College
$269 thousand
Lgenia Inc.
$255 thousand
Cummins Technical Center
$227 thousand
Marian University
$76 thousand

Indiana's top areas of global health R&D by USG funding

Flioviral diseases (including Ebola, Marburg)
Neglected tropical diseases
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Reproductive health
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Diarrheal diseases
Emergent non-polio enteroviruses (including EV71, D68)
Hepatitis B
Multi-disease/health area R&D
Salmonella infections
Global health R&D at work in Indiana

Researchers from the University of Notre Dame are conducting clinical trials to test the effectiveness of spatial repellents in preventing mosquito-borne diseases, including dengue and malaria. Spatial repellents release chemicals (a common example is a mosquito candle) that can help stop the spread of disease where existing tools, such as bednets and indoor residual spraying, are not entirely effective. New strategies are needed to avert the estimated 390 million cases of dengue and 247 million cases of malaria that occur each year globally. The project will generate data to inform disease control programs.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: Peace Corps